But with the rapid growth of the cell and gene therapy sector the demand for innovative technologies to improve process development and facilitate manufacturing scale-up, currently outstrips supply and could delay the commercialization of rAAV products, says Polyplus-transfection.
Based in a science park near Strasbourg, the producer maintains that it is one of the few companies working with viral vector manufacturers to combat this problem. Last week, Polyplus announced the official release of its transfection reagent - FectoVIR-AAV GMP – specifically for large scale manufacturing, which is said to complement its existing reagent line.
The company has also been scaling up of late in order to ensure it can supply transfection reagents to the CGT sector for the next two decades; April 2020 saw a major investment in the developer from Warburg Pincus and ArchiMed. Then, in January 2021, Polyplus initiated construction of Vectura, its major new 4,000m2 HQ and central facility in Strasbourg, which is nearing completion. Furthermore, in March this year, it acquired Biowire, a firm specializing in supporting life sciences tool and reagent companies to expand into Asia-Pacific.
New transfection reagent
FectoVIR-AAV GMP has been added to its transfection reagent portfolio to help manufacturers alleviate major pain points with linear process scalability and flexibility. Users will be able to work from small scale process development stages to improve AAV production in suspension cell culture systems and more easily transition into large-scale GMP manufacturing activities, said the company.